SLC5A2 and diabetes mellitus: SGLT-2 inhibitors showed higher DR risk with higher HbA1C level at the start of the therapy (Table S7), and when comparing GLP-1RA to DPP-4i, older age and longer duration of diabetes at baseline lowered the DR risk in favor of the GLP-1RA group (Tables S8 and S9).